🧵 5. Lilly's weight-loss treatments continue to face overwhelming demand. Novo Nordisk missed expectations in the latest quarter in this competitive market.
You are viewing a single comment's thread from:
🧵 5. Lilly's weight-loss treatments continue to face overwhelming demand. Novo Nordisk missed expectations in the latest quarter in this competitive market.